<DOC>
	<DOCNO>NCT01551758</DOCNO>
	<brief_summary>This study design compare effectiveness safety Fluticasone Furoate/Vilanterol Inhalation Powder ( 100mcg Fluticasone Furoate ( ( FF ) , GW685698 ) /25mcg Vilanterol ( ( VI ) , GW642444 ) ) deliver daily via Novel Dry Powder Inhaler ( NDPI ) compare exist COPD maintenance therapy twelve month subject diagnose COPD . This Phase III multi-centre , randomise open label study . Subjects meet eligibility criterion randomise enter 12 month treatment period .</brief_summary>
	<brief_title>A Randomised Effectiveness Study Comparing Fluticasone Furoate ( FF , GW685698 ) /Vilanterol ( VI , GW642444 ) With Standard Treatment Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>This Phase III multi-centre , randomise open label study perform subject follow primary care diagnosis receive regular treatment COPD localise geographical region UK</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Bronchodilator Agents</mesh_term>
	<criteria>Subjects eligible enrolment study must meet following criterion : 1 . Type subject : Subjects document GP diagnosis COPD , currently receive maintenance therapy 2 . Informed consent : Subjects must able provide inform consent , consent sign date . Subjects must able complete electronic subject questionnaire allow proxy behalf . 3 . Gender Age : Male female subject age ≥40 year age Visit 1 A female eligible enter participate study : Nonchild bear potential ( i.e . physiologically incapable become pregnant , include female postmenopausal surgically sterile ) . Surgically sterile female define documented hysterectomy and/or bilateral oophorectomy tubal ligation . Postmenopausal female define amenorrhoeic great 1 year appropriate clinical profile , e.g . age appropriate , history vasomotor symptom . However questionable case , blood sample FSH &gt; 40MIU/ml estradiol &lt; 40pg/ml ( &lt; 140 pmol/L ) confirmatory . Or child bear potential negative urine pregnancy test Visit 2 , agree one highly effective acceptable contraceptive method use consistently correctly ( i.e . accordance approve product label instruction physician duration study Visit 2 end study ) . 4 . Subjects Exacerbation History 5 . Current COPD Maintenance Therapy Subjects meeting follow criterion must enrol study : 1 . Subjects life threaten condition ( e.g . low probability ( opinion GP/Investigator ) 12 month survival due severity COPD comorbid condition ) point entry study . 2 . Other diseases/abnormalities : Subjects historical current evidence uncontrolled clinically significant disease . Significant define disease , opinion GP/ Investigator , would put safety subject risk participation , would affect efficacy safety analysis disease/condition exacerbate study . 3 . Subjects unstable COPD , define occurrence follow 2 week prior Visit 2 : Acute worsen COPD manage subject corticosteroid antibiotic require treatment prescribed physician . 4 . Chronic user oral corticosteroid : Subjects , opinion GP/Investigator , consider chronic user oral corticosteroid respiratory indication ( unsure discus medical monitor prior screen ) 5 . Drug/food allergy : Subjects history hypersensitivity study medication ( e.g. , betaagonists , corticosteroid ) component inhalation powder ( e.g. , lactose , magnesium stearate ) . In addition , subject history severe milk protein allergy , opinion GP/ Investigator , contraindicate subject 's participation also exclude . 6 . Investigational Medications : A subject must use investigational drug treatment within 30 day prior Visit 2 within five halflives ( t½ ) prior investigational study ( whichever longer two ) . 7 . Subjects plan move away geographical area study conduct study period and/or subject consent medical record part electronic medical record database operational Salford area .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Exacerbation</keyword>
	<keyword>Adult</keyword>
	<keyword>COPD</keyword>
	<keyword>Respiratory</keyword>
</DOC>